SEC Form 25-NSE filed by HEXO Corp.

$HEXO
Pharmaceuticals and Biotechnology
Health Care
Get the next $HEXO alert in real time by email
NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
UNITED STATES
OMB APPROVAL
OMB Number: 3235-0080
Expires: March 31, 2018
Estimated average burden
hours per response: 1.7
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 25
NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number 001-38781
Issuer: HEXO Corp.
Exchange: Nasdaq Stock Market LLC
(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
Address: 3000 Solandt Road
Ottawa ONTARIO, CANADA K2K 2X2 CA
Telephone number: 819-743-3726
(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
Common shares
(Description of class of securities)
Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
17 CFR 240.12d2-2(a)(1)
17 CFR 240.12d2-2(a)(2)
17 CFR 240.12d2-2(a)(3)
17 CFR 240.12d2-2(a)(4)
Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
2023-06-22 By Tara Petta AVP
Date Name Title
1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $HEXO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$HEXO

DatePrice TargetRatingAnalyst
3/4/2022$1.00 → $1.25Hold → Speculative Buy
Canaccord Genuity
3/4/2022Hold → Speculative Buy
Canaccord Genuity
3/4/2022$1.20 → $0.90Neutral
Cantor Fitzgerald
1/27/2022$1.07 → $0.53Underperform → Hold
Jefferies
12/15/2021$2.00 → $0.80Neutral → Underperformer
CIBC
12/15/2021Neutral → Sector Underperform
CIBC
12/15/2021$2.10 → $1.20Neutral
Cantor Fitzgerald
10/29/2021$2.29 → $2.10Neutral
Cantor Fitzgerald
More analyst ratings

$HEXO
Press Releases

Fastest customizable press release news feed in the world

See more
  • HEXO Corp. Announces Completion of Acquisition by Way of Arrangement With Tilray Brands, Inc.

    HEXO Corp. (TSX:HEXO, NASDAQ:HEXO) ("HEXO" or the "Company") announced today the closing of the second of two tranches of the non-brokered private placement of Series 1 Preferred Shares (the "Private Placement") previously announced on June 1, 2023 and the subsequent completion of the transactions contemplated by the previously announced statutory plan of arrangement under section 182 of the Business Corporations Act (Ontario) (the "Arrangement") involving the Company and Tilray Brands, Inc. ("Tilray"). "On behalf of HEXO's board and management team, I'd like to extend our deepest thanks to the entire HEXO team for their continued commitment to our business and customers," said Charlie Bow

    $HEXO
    Pharmaceuticals and Biotechnology
    Health Care
  • HEXO Corp. Announces Receipt of Final Order for Arrangement With Tilray Brands, Inc.

    HEXO Corp. (TSX:HEXO, NASDAQ:HEXO) ("HEXO" or the "Company") announced today that the Ontario Superior Court of Justice (Commercial List) (the "Court") has granted the final order (the "Final Order") in connection with the previously announced statutory plan of arrangement under section 182 of the Business Corporations Act (Ontario) (the "Arrangement"), pursuant to which Tilray Brands, Inc. ("Tilray") will acquire all of the issued and outstanding common shares (the "Common Shares") and non-voting Series 1 Preferred Shares of the Company. Holders of Common Shares of the Company (the "Common Shareholders") will receive 0.4352 of a share of Tilray common stock (the "Tilray Shares") for each w

    $HEXO
    Pharmaceuticals and Biotechnology
    Health Care
  • HEXO Reports Q3'23 Financial Results

    HEXO Corp. (TSX:HEXO, NASDAQ:HEXO) ("HEXO" or the "Company"), a leading producer of high-quality cannabis products, today reported its financial results for the third quarter of the 2023 fiscal year ("Q3'23"). All currency amounts are stated in Canadian dollars unless otherwise noted. "In the third quarter, we entered into a definitive arrangement agreement whereby Tilray will acquire all outstanding shares of HEXO," said Charlie Bowman, President and Chief Executive Officer of HEXO. "We continue to expect the transaction will be completed by June 30, 2023." "HEXO recorded $21.6 million in net revenues in the third quarter, representing an 11% decline from the second quarter," noted Jul

    $HEXO
    Pharmaceuticals and Biotechnology
    Health Care

$HEXO
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$HEXO
SEC Filings

See more

$HEXO
Leadership Updates

Live Leadership Updates

See more
  • HEXO Announces Election of Directors

    HEXO Corp. (TSX:HEXO, NASDAQ:HEXO) ("HEXO"), a leading producer of high-quality cannabis products, today announced that at the annual general meeting of shareholders held on January 31, 2023 (the "Meeting"), each of the eight director nominees was elected as a director of HEXO. Detailed results of the vote are set out below. Nominee Votes For Votes Withheld Total Votes Cast Percentage of Votes For Percentage of Votes Withheld Mark Attanasio 2,063,211 434,874 2,498,058 82.592% 17.408% Vincent Chiara 1,983,425 514,662 2,498,087 79.398% 20.602% Denise Faltischek 2,072,889 425,198 2,498,087 82.979% 17.021% Hélène

    $HEXO
    Pharmaceuticals and Biotechnology
    Health Care
  • HEXO Announces Leadership Transition; Company Appoints Charlie Bowman as Chief Executive Officer and Julius Ivancsits as Chief Financial Officer

    Scott Cooper Steps Down; Board of Directors Acknowledge Cooper in Stabilizing the Company Bowman and Ivancsits to Lead HEXO's Continued Transformation and Growth GATINEAU, Quebec, April 29, 2022 (GLOBE NEWSWIRE) -- HEXO Corp ("HEXO" or the "Company") (TSX:HEXO, NASDAQ:HEXO) today announced that Charlie Bowman has been appointed the Company's acting President and Chief Executive Officer, effective today. Mr. Bowman will move into a permanent role upon the successful completion of Health Canada's security clearance process for key personnel, which has been initiated. Concurrently, Scott Cooper is stepping down from his role as HEXO's President and Chief Executive Officer. "I am honoured t

    $HEXO
    Pharmaceuticals and Biotechnology
    Health Care
  • HEXO Announces the Appointment of a New Board Member and Acting CFO

    This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated May 11, 2021 to its short form base shelf prospectus dated May 7, 2021 and amended and restated on May 25, 2021. GATINEAU, Quebec, Jan. 05, 2022 (GLOBE NEWSWIRE) -- HEXO Corp ("HEXO", or the "Company") (TSX:HEXO, NASDAQ:HEXO), today announced the appointment of William Todd Montour to the Company's Board of Directors following the resignation of Jason Ewart, effective immediately. "I am pleased to welcome Will to the Board, and I am confident that his experience in cannabis operations and commercialization will be invaluable to the Company as we enter our next stage of

    $HEXO
    Pharmaceuticals and Biotechnology
    Health Care

$HEXO
Financials

Live finance-specific insights

See more
  • HEXO to Host Third Quarter 2023 Earnings Conference Call

    This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated May 2, 2022 to its short form base shelf prospectus dated May 7, 2021 and amended and restated on May 25, 2021 HEXO Corp. (TSX:HEXO, NASDAQ:HEXO) ("HEXO" or the "Company"), a leading producer of high-quality cannabis products, announced today that it will hold an audio-only conference call on Thursday, June 15, 2023, at 10 a.m. EDT, to review its financial results for the third fiscal quarter, ended April 30, 2023. The results will be released after market close on Wednesday, June 14, 2023. Following the prepared remarks, there will be a question-and-answer session. Ch

    $HEXO
    Pharmaceuticals and Biotechnology
    Health Care
  • Tilray Brands Reports Third Quarter Fiscal Year 2023 Financial Results and Announces Accretive Acquisition of 100% of HEXO Corp.

    Delivered $145.6 Million in Net Revenue and 16th Consecutive Quarter of Positive Adjusted EBITDA Maintained #1 Cannabis Market Share Position in Canada, the Largest Federally Legal Cannabis Market in the World; With HEXO Transaction, Poised to Substantially Increase Canadian Revenue Medical Cannabis Leader in Europe Achieved Key Efficiency Milestones on Accelerated Path to Positive Cash Flow, Company Reiterates Cash Flow Guidance LEAMINGTON, Ontario and NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) --  Tilray Brands, Inc. ("Tilray" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide commun

    $HEXO
    $TLRY
    Pharmaceuticals and Biotechnology
    Health Care
    Medicinal Chemicals and Botanical Products
  • HEXO to Host Second Quarter 2023 Earnings Conference Call

    This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated May 2, 2022 to its short form base shelf prospectus dated May 7, 2021 and amended and restated on May 25, 2021 HEXO Corp. (TSX:HEXO, NASDAQ:HEXO) ("HEXO" or the "Company"), a leading producer of high-quality cannabis products, announced today that it will hold an audio only conference call on March 17, 2023, at 10 a.m. EDT, to review its financial results for the second fiscal quarter, ended January 31, 2023. The results will be released after market close on Thursday, March 16, 2023. Following the prepared remarks, there will be a question-and-answer session. Charlie Bo

    $HEXO
    Pharmaceuticals and Biotechnology
    Health Care

$HEXO
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more